



These additions and changes are effective 4/17/26

Pharmacy Benefit Additions

These apply to Exchange only.

- **Brinsupri (brensocatic)** – Pharmacy benefit, Non preferred brand, PA and QL of 30 per 30 days
- **Wayrilz (rilzabrutinib)** – Pharmacy benefit, Non preferred brand, PA
- **Blujepa (gepotidacin)** – Pharmacy benefit, Non Formulary
- **Exxua (gepirone)** – Pharmacy benefit, Non Formulary
- **Modeyso (dordaviprone)** – Pharmacy benefit, Non preferred brand, PA
- **Inluriyo (imlunestrant)** – Pharmacy benefit, Non preferred brand, PA
- **Komzifti (ziftomenib)** – Pharmacy benefit, Non preferred brand, PA
- **Wegovy (semaglutide)** – Pharmacy benefit, Excluded

Pharmacy Benefit Changes

These apply to Exchange only.

- **Tremfya (guselkumab)** – Pharmacy benefit, Criteria update
- **Repatha (evolocumab)** – Pharmacy benefit, Criteria update

Medical Benefit Additions/Changes

These apply to Medicare and Exchange.

- **Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)** – Medical benefit, PA
- **Lunsumio Velo (mosunetuzumab-axgb)** – Medical benefit, PA
- **Xtrenbo/Enoby (denosumab-qbde)** – Medical benefit, PA
- **Durolane (hyaluronic acid)** – Medical benefit, Remove PA and add to PSCE (effective 3/15/26)